Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Creating an Automated High-Throughput Flow Cytometry System

By SLAS (Society for Laboratory Automation and Screening) | May 30, 2018

This is a computer aided design (CAD) of the screening system. Credit: Genomics Institute of the Novartis Research Foundation (GNF)

A new SLAS Discovery original research article available now for free ahead-of-print, researchers from the Genomics Institute of the Novartis Research Foundation (GNF) highlights a diversity of approaches that their automated high-throughput flow cytometry has enabled for phenotypic drug discovery.

Flow cytometry is a very powerful tool that has been used for decades and allows for multiparametric readouts at the single cell level within heterogeneous cell populations. However, in the context of high-throughput screening, flow cytometry is slow, low-throughput, and is not amenable to automation.

The GNF group has developed a fully automated screening system that solves this problem. The system can achieve a throughput of 50,000 wells per day, resulting in a fully automated platform that enables robust phenotypic drug discovery.

Over the past five years, this screening system has been used for a variety of drug discovery programs, across many disease areas, with many molecules advancing quickly into preclinical development and into the clinic.

Pharmaceutical companies are tasked with finding new drugs that provide real benefit to patients. A common approach is through the use of phenotypic screening. This is dependent upon the ability to establish complex, biologically relevant screening assays and run high-throughput screening campaigns. However, this kind of complex biology requires new methodologies for lead identification and screening systems like the one developed by the GNF team.

SOURCE: SLAS (Society for Laboratory Automation and Screening)


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE